|
1
|
Wang ZY and Chen Z: Acute promyelocytic
leukemia: from highly fatal to highly curable. Blood.
111:2505–2515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kogan SC: Curing APL: differentiation or
destruction? Cancer Cell. 15:7–8. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hoffman E and Mielicki WP: All-trans
retinoic acid (ATRA) in prevention and cancer therapy. Postepy Hig
Med Dosw (Online). 64:284–290. 2010.(In Polish).
|
|
4
|
Wang T, Ma X, Krausz KW, Idle JR and
Gonzalez FJ: Role of pregnane X receptor in control of all-trans
retinoic acid (ATRA) metabolism and its potential contribution to
ATRA resistance. J Pharmacol Exp Ther. 324:674–684. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yin T, Wu YL, Sun HP, et al: Combined
effects of As4S4 and imatinib on chronic
myeloid leukemia cells and BCR-ABL oncoprotein. Blood.
104:4219–4225. 2004.
|
|
6
|
Wu J, Shao Y, Liu J, Chen G and Ho PC: The
medicinal use of realgar (As4S4) and its
recent development as an anticancer agent. J Ethnopharmacol.
135:595–602. 2011.PubMed/NCBI
|
|
7
|
Qi J, He PC, Chen W, Wang H, Wang X and
Zhang M: Comparative proteome study of apoptosis induced by
As4S4 in retinoid acid resistant human acute
promyelocytic leukemia NB4-R1 cells. Leuk Res. 34:1506–1516. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pecot CV, Calin GA, Coleman RL,
Lopez-Berestein G and Sood AK: RNA interference in the clinic:
challenges and future directions. Nat Rev Cancer. 11:59–67. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hannon GJ: RNA interference. Nature.
418:244–251. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun BS, Dong QZ, Ye QH, et al:
Lentiviral-mediated miRNA against osteopontin suppresses tumor
growth and metastasis of human hepatocellular carcinoma.
Hepatology. 48:1834–1842. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gallagher R: Retinoic acid resistance in
acute promyelocytic leukemia. Leukemia. 16:1940–1958. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sanz MA, Grimwade D, Tallman MS, et al:
Management of acute promyelocytic leukemia: recommendations from an
expert panel on behalf of the European LeukemiaNet. Blood.
113:1875–1891. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yin T, Wu YL, Sun HP, et al: Combined
effects of As4S4 and imatinib on chronic
myeloid leukemia cells and BCR-ABL oncoprotein. Blood.
104:4219–4225. 2004.
|
|
14
|
Wang L, Zhou GB, Liu P, et al: Dissection
of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis
as an effective treatment for promyelocytic leukemia. Proc Natl
Acad Sci USA. 105:4826–4831. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang N, Wang LW, Gou BD, Zhang TL and Wang
K: Realgar-induced differentiation is associated with MAPK pathways
in HL-60 cells. Cell Biol Int. 32:1497–1505. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhao W, Lu X, Yuan Y, et al: Effect of
size and processing method on the cytotoxicity of realgar
nanoparticles in cancer cell lines. Int J Nanomedicine.
6:1569–1577. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Janssens V and Rebollo A: The role and
therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic
signalling networks in human cancer cells. Curr Mol Med.
12:268–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Switzer CH, Cheng RYS, Vitek TM,
Christensen DJ, Wink DA and Vitek MP: Targeting SET/I2PP2A
oncoprotein functions as a multi-pathway strategy for cancer
therapy. Oncogene. 30:2504–2513. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Krajewski WA and Vassiliev OL: Histone
acetylation facilitates association of nucleosomes with SET domain
of ALL-1 methyltransferase in vitro. Biochem Biophys Res Commun.
397:112–116. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu J, Kovach JS, Johnson F, et al:
Inhibition of serine/threonine phosphatase PP2A enhances cancer
chemotherapy by blocking DNA damage induced defense mechanisms.
Proc Natl Acad Sci USA. 106:11697–11702. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ratcliffe MJ, Itoh K and Sokol SY: A
positive role for the PP2A catalytic subunit in Wnt signal
transduction. J Biol Chem. 275:35680–35683. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sontag E, Nunbhakdi-Craig V, Bloom GS and
Mumby MC: A novel pool of protein phosphatase 2A is associated with
microtubules and is regulated during the cell cycle. J Cell Biol.
128:1131–1144. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kolupaeva V, Laplantine E and Basilico C:
PP2A-mediated dephosphorylation of p107 plays a critical role in
chondrocyte cell cycle arrest by FGF. PLoS One. 3:e34472008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Aranda-Orgilles B, Rutschow D, Zeller R,
et al: Protein phosphatase 2A (PP2A)-specific ubiquitin ligase MID1
is a sequence-dependent regulator of translation efficiency
controlling 3-phosphoinositide-dependent protein kinase-1 (PDPK-1).
J Biol Chem. 286:39945–39957. 2011. View Article : Google Scholar
|
|
25
|
Sablina AA and Hahn WC: SV40 small T
antigen and PP2A phosphatase in cell transformation. Cancer
Metastasis Rev. 27:137–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gordon J, Hwang J, Carrier KJ, et al:
Protein phosphatase 2a (PP2A) binds within the oligomerization
domain of striatin and regulates the phosphorylation and activation
of the mammalian Ste20-Like kinase Mst3. BMC Biochem. 12:542011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guergnon J, Godet AN, Galioot A, et al:
PP2A targeting by viral proteins: a widespread biological strategy
from DNA/RNA tumor viruses to HIV-1. Biochim Biophys Acta.
1812:1498–1507. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cristobal I, Blanco FJ, Garcia-Orti L, et
al: SETBP1 overexpression is a novel leukemogenic mechanism that
predicts adverse outcome in elderly patients with acute myeloid
leukemia. Blood. 115:615–625. 2010. View Article : Google Scholar
|
